EP1963265A1 - Procede de fabrication de perindopril et de sels de perindopril - Google Patents

Procede de fabrication de perindopril et de sels de perindopril

Info

Publication number
EP1963265A1
EP1963265A1 EP06829234A EP06829234A EP1963265A1 EP 1963265 A1 EP1963265 A1 EP 1963265A1 EP 06829234 A EP06829234 A EP 06829234A EP 06829234 A EP06829234 A EP 06829234A EP 1963265 A1 EP1963265 A1 EP 1963265A1
Authority
EP
European Patent Office
Prior art keywords
solvent
iii
mixture
water
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06829234A
Other languages
German (de)
English (en)
Inventor
Chen Weiren
Shi Jiaxiang
Lu Biao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KRKA dd
Original Assignee
KRKA Tovarna Zdravil dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KRKA Tovarna Zdravil dd filed Critical KRKA Tovarna Zdravil dd
Priority to EP06829234A priority Critical patent/EP1963265A1/fr
Publication of EP1963265A1 publication Critical patent/EP1963265A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Definitions

  • This invention relates to a process for the preparation of perindopril and salts thereof as well as to processes for pu- rifying intermediates used in this preparation.
  • Perindopril is the generic name of (2S, 3aS, 7aS) -1- ( (2S) -2- ( ( (IS) -1- (ethoxycarbonyl) butyl) amino) -1-oxopropyl) octahydro- lH-indol-2-carboxylic acid.
  • Perindopril and its salts, pref- erably the t-butylamine salt thereof, referred to as perindopril erbumine, are compounds having ACE inhibitory action and are therefore useful for the treatment of hypertension.
  • perindopril is prepared by coupling N- ((S)-I- carbethoxybutyl) - (S) -alanine or an activated derivative thereof with an ester and/or salt of (2S, 3aS, 7aS) - octahydroindole-2-carboxylic acid.
  • EP 308 341 teaches a large-scale synthesis of perindopril in the form of the t-butylamine salt.
  • EP 308 340 teaches to condense (S) -norvaline ethyl ester hydrochloride with pyruvic acid in an aqueous medium to give a high proportion of the diastereomer of the alanine intermediate in which both asymmetric carbon atoms have the (S)- configuration and to isolate the obtained diastereomer by one single crystallization from a polar organic solvent carefully selected from acetonitrile, ethyl acetate and lower aliphatic alcohol alone or mixed with each other or with water.
  • WO 01/56353 discloses a method for the industrial synthesis of the alanine intermediate, wherein sodium pyruvate is condensed with (S) -norvaline ethyl ester hydrochloride by hydrogenation in water in the presence of a specific amount of sodium hydroxide. After hydrogenation the reaction mixture is acidified and filtered to give directly the alanine intermediate.
  • WO 2005/100317 describes a simplified process step for preparing (2S, 3aS, 7aS) -octahydroind ⁇ le-2-carboxylic acid by hydro- genation of (S) -indoline-2-carboxylic acid under reduced pressure conditions in an alkaline medium including a recrystalli- zation of the intermediate from acetonitrile. Subsequently, a substituted benzyl ester of (2S, 3aS, 7aS) -octahydroindole-2- carboxylic acid is coupled with the alanine intermediate to give perindopril which is converted into perindopril erbumine.
  • the invention is also directed to a process for preparing N- ( (S) -1-carbethoxybutyl) - (S) -alanine, or an activated or protected form or a salt thereof, in purified form according to claims 16 and 17 and a process for preparing (2S, 3aS, 7aS) - - - -
  • a solvent selected from the group consisting of tet- rahydrofuran, dimethyl carbonate, diethyl carbonate, 1, 2-dimethoxy ethane, tert. -butyl methyl ether, 2- methyl tetrahydrofuran, cyclopentyl methyl ether and mixtures thereof,
  • a particularly preferred pharmaceutically acceptable salt of perindopril is the tert . -butylamine salt, i.e. perindopril er- bumine.
  • N- ((S)-I- carbethoxybutyl) - (S) -alanine or an activated form or a protected form or a salt thereof can be used as an intermediate in the synthesis of perindopril (intermediate (i) ) .
  • activated form is intended to include derivatives of N- ((S)-I- carbethoxybutyl) - (S) -alanine which have been formed by reacting with commonly used coupling agents known in the art such - -
  • N,N-thionyldiimidazole ⁇ N-dicyclohexylcarbodiimide and 1- hydroxybenzotriazole.
  • These agents may convert the acid group of the alanine to groups which are more reactive in peptid coupling reactions, e.g. an acid chloride.
  • the term "protected form” is intended to include derivatives of N- ((S)- 1-carbethoxybutyl) - (S) -alanine in which functional groups and in particular the amine group of the alanine has been protected with usual protecting groups such as acyl, silyl groups, and carbamides .
  • salts of N- ((S)-I- carbethoxybutyl) - (S) -alanine such as the hydrochloride salt can be used as intermediate (i) .
  • (2S, 3aS, 7aS) -octahydroindole-2-carboxylic acid or an activated form or a protected form or a salt thereof can be used as an intermediate in the present process (intermediate (ii) ) .
  • the term "activated form” is intended to include derivatives of (2S, 3aS, 7aS) -octahydroindole-2-carboxylic acid which are formed upon reaction with commonly used coupling agents known in the art such as N,N-thionyldiimidazole, N, N- dicyclohexylcarbodiimide and 1-hydroxybenzotriazole.
  • protected form is intended to include derivatives of (2S, 3aS, 7aS) -octahydroindole-2-carboxylic acid in which functional groups and in particular the acid group are protected by a protecting group such as benzyl, substituted benzyl, t- butyl or trimethylsilyl .
  • the intermediate (ii) can also be a salt of (2S, 3aS, 7aS) -octahydroindole-2-carboxylic acid such as the potassium, lithium or sodium salt.
  • perindopril of high quality and purity is provided without substantial amounts of byproducts by using intermediate (i) and/or intermediate (ii) in a purified form, wherein the purified form has been prepared by using solvent (iii) or a mixture of solvent (iii) and water.
  • solvent (iii) or a mixture of solvent (iii) and water it has been found that both the chemical purity and the enantiomeric purity is increased by the method of the invention.
  • THF tetrahydrofuran
  • intermediate (i) is N- ( (S) -1-carbethoxybutyl) - (S) -alanine .
  • the purified form of intermediate (i) is prepared by a recrystallization from solvent (iii) or a mixture of solvent (iii) and water.
  • THF is used as solvent (iii), i.e. the purified form of intermediate (i) is preferably prepared by a recrystallization from THF or a mixture of THF and water.
  • the purified form of the alanine intermediate (i) is prepared by multiple recrys- tallizations such as 2 or 3 recrystallizations from solvent (iii) or a mixture of solvent (iii) and water.
  • step (b) optionally adding charcoal to the suspension of step (a), (c) heating the suspension of step (a) or (b) to obtain a solution of intermediate (i) , preferably heating to reflux, (d) filtering the solution of step (c) , - -
  • step (e) optionally adding water to the filtrate of step (d) ,
  • step (f) the filtrate or mixture is cooled to a temperature of about -20 to about 30 0 C, preferably of about 0 to about 25 0 C and more prefarably of about 10 to about 25 0 C.
  • the ratio of solvent (iii) to water ranges from 0.5:1 to 100:1, preferably 1:1 to 50:1 and more preferably 5:1 to 30:1.
  • These mixing ratios of solvent (iii) and water can be achieved by initially mixing the solvents before contacting them with the alanine intermediate to be purified or by firstly mixing one of the solvents with the alanine intermediate and adding the other solvent at a later step of the purification procedure as it is for example provided in step (e) of the above described preferred recrystallization method.
  • intermediate (ii) is used in the synthesis of perindopril. It is particularly preferred that intermediate (ii) is (2S, 3aS, 7aS) -octahydroindole-2-carboxylic acid. — o —
  • the purified form of the indole intermediate (ii) is prepared by a recrystallization from solvent (iii) or a mixture of solvent (iii) and water.
  • a mixture of solvent (iii) and water is used for recrystallizing intermediate (ii) .
  • the ratio by volume of solvent (iii) to water ranges from 0.5:1 to 50:1, preferably 1:1 to 20:1 and more preferably 2:1 to 8:1.
  • the recrystallization of the in- dole intermediate (ii) comprises
  • step (a) heating a mixture of crude intermediate (ii) , solvent (iii) and water to give a solution, preferably heating to reflux, (b) optionally filtering the solution of step (a) ,
  • step (c) cooling the solution of step (a) or the filtrate of step (b) to precipitate purified intermediate (ii) , and
  • the indole intermediate (ii) is purified by a recrystallization comprising
  • step (b 1 ) adding solvent (iii) to the solution of step (a), (c 1 ) cooling the solution of step (b) to precipitate purified intermediate (ii) , and (d 1 ) collecting the obtained intermediate (ii) .
  • step (c) or (c 1 ) the solution of step (a), (a 1 ) or (b 1 ) or the filtrate of step (b) is cooled to a temperature of about -20 to about 30 0 C, preferably to a temperature of about 0 to about 25 0 C and more preferably to a temperature of about 10 to about 25 0 C, in order to effect the precipitation of the purified indole intermediate.
  • step (d) or (d 1 ) the solution is kept at the precipitation temperature of step (c) or (c 1 ) for 0.5 to 6 h, preferably for 1 to 3 h.
  • intermediate (ii) which has been purified according to the invention may be further washed with solvent (iii) or a mixture of solvent (iii) and water, and is particularly washed with solvent (iii) .
  • solvent (iii) preferably, for washing intermediate (ii) THF is used as solvent (iii) .
  • this invention further includes a process for preparing inter- mediate (i) selected from N- ( (S) -1-carbethoxybutyl) - (S) - alanine or an activated or protected form or a salt thereof in a purified form, wherein crude intermediate (i) is purified by using solvent (iii) or a mixture of solvent (iii) and water.
  • the purified form of the alanine intermediate (i) is prepared by a recrystallization from solvent (iii) or a mixture of solvent (iii) and water. It is particularly preferred to use THF as solvent (iii) for purifying the alanine intermediate (i) .
  • the invention also relates to a process for preparing intermediate (ii) selected from (2S, 3aS, 7aS) - octahydroindole-2-carboxylic acid or an activated or protected form or salt thereof in a purified form, wherein crude inter- - -
  • mediate (ii) is purified by using solvent (iii) or a mixture of solvent (iii) and water.
  • the purified form of the indole intermediate (ii) is prepared by a recrystalli- zation from solvent (iii) or a mixture of solvent (iii) and water.
  • a mixture of solvent (iii) and water is used.
  • the present invention is further illustrated by the following Examples.
  • Step A Preparation of N- ( (S) -1-carbethoxybutyl) - (S) -alanine
  • Ethyl L-norvalinate hydrochloride 80 g, 0.44 M
  • 200 ml of ethanol 95 %) were charged into a hydrogenator .
  • Pyruvic acid 40 g, 0.454 M
  • 16 g of 10 % Pd/C were added to the mixture, the nitrogen atmosphere was replaced by hydrogen and the mixture was hydrogenated at 3O 0 C and a pressure of 30 bar under stirring for 2 days.
  • the cata- lyst was filtered off and the filtrate was neutralized with ⁇ sodium hydroxide.
  • the neutralized filtrate was concentrated to dryness under reduced pressure. The residue obtained after evaporation was suspended in ethanol.
  • the suspension was filtered to remove any undissolved material and evaporated under reduced pressure.
  • the crude residue was taken up in 560 ml of tetrahydrofurane (THF) . Charcoal was added and the suspension was heated to its boiling point and filtered. The filtrate was then cooled to 20 0 C - 25 0 C.
  • the precipitated solid was col- _
  • This product could be employed in the further synthesis of perindopril without any additional treatment, in particular purification.
  • Step B Preparation of (2S, 3aS, 7aS) octahydro-lH-indol-2- carboxylic acid
  • Ethyl (S) -indoline-2-carboxylate hydrochloride (30 g, 0.13 M), 300 ml of ethanol and 3 g of 7.5 % Pd/C were charged under nitrogen into a hydrogenator . The nitrogen atmosphere was 3 times replaced with fresh nitrogen and 5 times with hydrogen. The reaction mixture was hydrogenated at 60°C and 50 bar under stirring until the hydrogen had been consumed. The catalyst was filtered off and 28 ml of sodium hydroxide (30 %) were added to the filtrate. The mixture was stirred at 30 0 C for 5 h. After hydrolysis, the pH was adjusted to 4.5 using 37% aqueous HCl. Sodium chloride was removed by filtration and the filtrate was concentrated under reduced pressure.
  • Step C Silylation of (2S, 3aS, 7aS) octahydro-lH-indol-2- carboxylic acid
  • Trimethyl chlorosilane 29.3 ml, 0.22M
  • trietylamine 30.7 ml, 0.22 M
  • (2aS, 3aS, 7aS) - octahydro-lff-indole-2-carboxylic acid 18,6 g 0.11M
  • the mixture was stirred for 3 h at 20 to 25°C.
  • Step D Activation of N- ( (S) -1-carbethoxybutyl) - (S) -alanine with N, N-thionyldiimidazole
  • Step E Preparation of perindopril erbumin ( (2S, 3aS, 7aS) -1- ( (2S) -2- ( ( (IS) -1- (ethoxycarbonyl) butyl) amino) -1-oxo- propyl) octahydro-lH-indol-2-carboxylic acid 2-methylpropane-2- amine salt)
  • L-norvaline ethyl ester hydrochloride (50 g) , 300 ml of etha- nol and pyruvic acid sodium salt (31.8 g) were hydrogenated in the presence of 5 g of 7.5 % Pd/C (dry basis) for 40 h at 40 0 C and at a pressure of 3 MPa. Then, the mixture was filtered to remove the catalyst and sodium chloride. The filtrate was evaporated to dryness. 300 ml of THF were added and the mixture was heated to reflux for 30 minutes and then filtered. 45 ml of water were added to the clear filtrate and the solution was cooled to 10 0 C for crystallization. The obtained solid was collected and dried at 70 0 C for 6 h to give 24 g of N-
  • L-norvaline ethyl ester hydrochloride 100 g
  • 400 ml of etha- nol, 30 % aqueous sodium hydroxide solution (73.3 g) and pyruvic acid (51.7 g) were hydrogenated in the presence of 10 g of 7.5 % Pd/C (dry basis) for 10 h at 40 0 C and at a pressure of 3 MPa.
  • the mixture was filtered to remove the catalyst and sodium chloride.
  • the filtrate was evaporated to dryness. 700 ml of THF were added and the mixture was heated to reflux for 30 minutes and then filtered to remove sodium chloride.
  • L-norvaline ethyl ester hydrochloride 50 g
  • 280 ml of 95 % ethanol and pyruvic acid sodium salt 31.8 g
  • 5 g of 7.5 % Pd/C dry basis
  • the mixture was filtered to remove the catalyst and sodium chloride.
  • the filtrate was evaporated to dryness.
  • 350 ml of THF were added and the mixture was heated to reflux for 30 minutes and then filtered to remove sodium chloride. The filtrate was cooled to 10 0 C for crystallization.
  • the same yield and optical rotation can be obtained by using 50 ml of water and 200 ml of THF at 65 0 C instead of water and 1, 2-dimethoxyethane .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)

Abstract

La présente invention concerne un procédé de fabrication de l’inhibiteur d'ACE (acide (2S, 3aS, 7aS)-1-((2S)-2-(((1S)-1-(éthoxycarbonyl)butyl)amino)-1-oxopropyl) octahydro-1H-indol-2-carboxylique) et de sels pharmaceutiquement acceptables de ce composé, ainsi que des procédés de fabrication d'un intermédiaire N-((S)-I- carbéthoxybutyl)-(S)-alanine et d’un intermédiaire acide (2S, 3aS, 7aS)-octahydroindole-2-carboxylique sous forme purifiée.
EP06829234A 2005-12-01 2006-12-01 Procede de fabrication de perindopril et de sels de perindopril Withdrawn EP1963265A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06829234A EP1963265A1 (fr) 2005-12-01 2006-12-01 Procede de fabrication de perindopril et de sels de perindopril

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05026160A EP1792896A1 (fr) 2005-12-01 2005-12-01 Procédé pour la préparation de perindopril et de ses sels
EP06829234A EP1963265A1 (fr) 2005-12-01 2006-12-01 Procede de fabrication de perindopril et de sels de perindopril
PCT/EP2006/011558 WO2007062865A1 (fr) 2005-12-01 2006-12-01 Procede de fabrication de perindopril et de sels de perindopril

Publications (1)

Publication Number Publication Date
EP1963265A1 true EP1963265A1 (fr) 2008-09-03

Family

ID=36147068

Family Applications (2)

Application Number Title Priority Date Filing Date
EP05026160A Withdrawn EP1792896A1 (fr) 2005-12-01 2005-12-01 Procédé pour la préparation de perindopril et de ses sels
EP06829234A Withdrawn EP1963265A1 (fr) 2005-12-01 2006-12-01 Procede de fabrication de perindopril et de sels de perindopril

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP05026160A Withdrawn EP1792896A1 (fr) 2005-12-01 2005-12-01 Procédé pour la préparation de perindopril et de ses sels

Country Status (2)

Country Link
EP (2) EP1792896A1 (fr)
WO (1) WO2007062865A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI22543A (sl) 2007-06-27 2008-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Nove soli perindoprila

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508729A (en) * 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
IE52663B1 (en) 1980-04-02 1988-01-20 Warner Lambert Co Substituted acyl derivatives of octahydro-1h-indole-2-carboxylic acids
FR2620700B1 (fr) 1987-09-17 1990-06-01 Adir Procede de synthese d'alpha amino acides n alkyles et leurs esters. application a la synthese de carboxyalkyl dipeptides
FR2620709B1 (fr) 1987-09-17 1990-09-07 Adir Procede de synthese industrielle du perindopril et de ses principaux intermediaires de synthese
FR2620703B1 (fr) 1987-09-17 1991-10-04 Adir Procede de synthese industrielle de l'acide perhydroindole carboxylique - 2(2s, 3as, 7as). application a la synthese de carboxyalkyl dipeptides
FR2620699B1 (fr) 1987-09-17 1990-06-01 Adir Procede de synthese d'alpha amino acides n alkyles et de leurs esters. application a la synthese de carboxyalkyl dipeptides
US5258525A (en) * 1991-03-27 1993-11-02 Mcneilab, Inc. Processes for preparing [2S-(2α,3aβ,7aβ)]octahydro-1H-indole-2-carboxylic acid and esters
NL1008302C2 (nl) 1998-02-13 1999-08-16 Dsm Nv Werkwijze voor de bereiding van een optisch actief indoline-2-carbonzuur of derivaat daarvan.
FR2807037B1 (fr) 2000-03-31 2002-05-10 Adir NOUVEAU PROCEDE DE SYNTHESE DES ESTERS DE LA N-[(s)-1- CARBOXYBUTYL]-(S)-ALANINE ET APPLICATION A LA SYNTHESE DU PERINDOPRIL
FR2807430B1 (fr) 2000-04-11 2002-05-17 Adir Nouveau procede de synthese des esters de la n-[(s)-1- carboxybutyl]-(s)-alanine et application a la synthese du perindopril
EP1333026B1 (fr) * 2002-01-30 2007-06-27 Les Laboratoires Servier Procédé de préparation de perindopril de grande pureté et des intermédiaires utiles dans la synthèse
PT1348684E (pt) 2003-04-09 2006-05-31 Servier Lab Novo processo de sintese do acido (2s)-indolina-2-carboxilico e aplicacao a sintese do perindopril
ES2240921T3 (es) * 2003-06-13 2005-10-16 Les Laboratoires Servier Procedimiento de sintesis del acido (2s,3as,7as)-perhidroindol-2-carboxilico y sus esteres y su utilizacion en la sintesis de perindopril.
PT1362845E (pt) 2003-09-01 2009-11-05 Servier Lab Novo processo de síntese dos ésteres da n-((s)-1- carboxibutil)-(s)-alanina e aplicação à síntese do perindopril
EP1400531B1 (fr) 2003-09-30 2006-01-04 Les Laboratoires Servier Procédé de synthèse de la N-[(S)-1-carbéthoxybutyl]-(S)-alanine et application à la synthèse du perindopril
GB2413128A (en) 2004-04-13 2005-10-19 Neopharma Ltd Process for the preparation of perindopril

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007062865A1 *

Also Published As

Publication number Publication date
EP1792896A1 (fr) 2007-06-06
WO2007062865A1 (fr) 2007-06-07

Similar Documents

Publication Publication Date Title
JP3939553B2 (ja) ペリンドプリル及びその薬学的に許容されうる塩の新規合成方法
JP3868957B2 (ja) （２Ｓ，３ａＳ，７ａＳ）−１−［（Ｓ）−アラニル］−オクタヒドロ−１Ｈ−インドール−２−カルボン酸化合物の新しい合成方法及びペリンドプリルの合成における応用
EP1420028B1 (fr) Pocédé de synthèse du perindopril et de ses sels pharmaceutiquement acceptables
JP3872344B2 (ja) Ｎ−〔（ｓ）−１−カルボキシブチル〕−（ｓ）−アラニンエステルの新規合成方法及びペリンドプリルの合成における適用
JP2007537189A (ja) ペリンドプリルまたはおよびその塩の調製のための方法
JP4347341B2 (ja) ペリンドプリル及びその薬学的に許容し得る塩の新規合成方法
JP3930322B2 (ja) Ｎ−〔（ｓ）−１−カルボキシブチル〕−（ｓ）−アラニンエステルの新規合成方法及びペリンドプリルの合成における適用
WO2005005461A2 (fr) Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables
JP4331207B2 (ja) ペリンドプリルおよびその薬学的に許容され得る塩の、新規な合成方法
EP1963265A1 (fr) Procede de fabrication de perindopril et de sels de perindopril
AU2005329237A1 (en) An improved process for the purification of perindopril
WO2005023841A1 (fr) Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables
WO2005023842A1 (fr) Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables
JP4263744B2 (ja) ペリンドプリル及びその薬学的に許容し得る塩の新規な合成方法
WO2009122433A2 (fr) Procédé de préparation de ramipril
JP4263743B2 (ja) ペリンドプリル及びその薬学的に許容し得る塩の新規な合成方法
AU2004218200A1 (en) Novel method for synthesising (2S, 3aS, 7aS)-perhydroindole-2-carboxylic acid and the esters thereof and the use thereof for perindopril synthesis
ES2233913T3 (es) Nuevo procedimiento de sintesis del acido (2s,3as,7as) perhidroindol-2-carboxilico y de sus esteres, y aplicacion as la sintesis de perindopril.
WO2007085933A2 (fr) Procede de preparation d’un complexe n-[1-(s)-ethoxycarbonyl-1-butyl]-(s)-alanine-dmt et son utilisation dans la preparation du perindopril
CA2768239A1 (fr) Procedes de synthese d'acide (2s, 3ar, 7as)-octahydro-1h-indole carboxylique comme intermediaire pour le trandolapril
WO2006137082A1 (fr) Procédé pour la préparation de périndopril erbumine viable industriellement
HU194912B (en) Process for producing alkylamino-furanone-dipeptide derivatives and acid additional salts thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080701

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BIAO, LU

Inventor name: JIAXIANG, SHI

Inventor name: WEIREN, CHEN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150701